132 related articles for article (PubMed ID: 11939825)
1. Onset of non-AIDS Kaposi sarcoma during therapy with interferon alfa-2a in an 82-year-old man with concomitant cutaneous T-cell lymphoma.
Giuliani M; Mastroianni A; Di Carlo A; Donati P; Miceli M; Monini P; Rezza G
Arch Dermatol; 2002 Apr; 138(4):535-7. PubMed ID: 11939825
[No Abstract] [Full Text] [Related]
2. Congestive heart failure in a patient with cutaneous T-cell lymphoma treated with low-dose interferon alfa-2b.
Evans KG; Loren AW; Rook AH; Kim EJ; Glassberg HL
Arch Dermatol; 2011 Sep; 147(9):1122-3. PubMed ID: 21931064
[No Abstract] [Full Text] [Related]
3. Cutaneous ulcers due to interferon seem not to be related to the dosage.
Virgili A; Corazza M; Lombardi AR; Sighinolfi L
J Eur Acad Dermatol Venereol; 1999 Sep; 13(2):141-3. PubMed ID: 10568497
[No Abstract] [Full Text] [Related]
4. Treatment of cutaneous T cell lymphoma stage II with interferon-alpha-2a and extracorporeal photochemotherapy: a prospective controlled trial.
Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
Ann N Y Acad Sci; 2001 Sep; 941():210-3. PubMed ID: 11594576
[No Abstract] [Full Text] [Related]
5. Interferon alpha and etretinate combination treatment of cutaneous T-cell lymphoma.
Zachariae H; Thestrup-Pedersen K
J Invest Dermatol; 1990 Dec; 95(6 Suppl):206S-208S. PubMed ID: 2258637
[TBL] [Abstract][Full Text] [Related]
6. An atypical aggressive Kaposi's sarcoma in a HIV-negative bisexual man.
Adedayo AO; Grell GA; Boada LG; Bellot P
West Indian Med J; 2001 Mar; 50(1):75-7. PubMed ID: 11398296
[TBL] [Abstract][Full Text] [Related]
7. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
J Am Acad Dermatol; 2001 Feb; 44(2):253-60. PubMed ID: 11174383
[TBL] [Abstract][Full Text] [Related]
8. Reversible diabetes in patient with AIDS-related Kaposi's sarcoma treated with interferon alpha-2a.
Gori A; Caredda F; Franzetti F; Ridolfo A; Rusconi S; Moroni M
Lancet; 1995 Jun; 345(8962):1438-9. PubMed ID: 7760627
[No Abstract] [Full Text] [Related]
9. [Activated C protein resistance manifested by cutaneous necrosis after interferon alpha injection: case report].
Plurien F; Le Lostec Z; Pauwels C; Welker Y; Glaser C; de Mazancourt P; Peltier JY; Mornet P
Rev Med Interne; 2000 Sep; 21(9):791-4. PubMed ID: 11039175
[TBL] [Abstract][Full Text] [Related]
10. Interferon alfa-2a.
Williams CD; Linch DC
Br J Hosp Med; 1997 May 7-20; 57(9):436-9. PubMed ID: 9274677
[TBL] [Abstract][Full Text] [Related]
11. Conjunctival Kaposi's sarcoma treated with interferon alpha-2a.
Hummer J; Gass JD; Huang AJ
Am J Ophthalmol; 1993 Oct; 116(4):502-3. PubMed ID: 8213983
[No Abstract] [Full Text] [Related]
12. A case report of iatrogenic cutaneous Kaposi sarcoma due to rituximab therapy for thrombotic thrombocytopenic purpura.
Jerdan K; Brownell J; Singh M; Braniecki M; Chan L
Acta Oncol; 2017 Jan; 56(1):111-113. PubMed ID: 27885868
[No Abstract] [Full Text] [Related]
13. Biological modifiers (etretinate (changed from etetrinate) and alfa 2a) in the treatment of refractory cutaneous T-cell lymphoma.
Avilés A; Guzmán R; García EL; Díaz-Maqueo JC
Cancer Biother Radiopharm; 1996 Feb; 11(1):21-4. PubMed ID: 10851517
[TBL] [Abstract][Full Text] [Related]
14. Alternating recombinant and natural alpha-interferon helps to prevent clinical resistance to interferon in cutaneous T-cell lymphoma treatment.
Altomare G; Capella GL; Frigerio E
Acta Derm Venereol; 1998 Mar; 78(2):159. PubMed ID: 9534907
[No Abstract] [Full Text] [Related]
15. Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS).
Krown SE; Gold JW; Niedzwiecki D; Bundow D; Flomenberg N; Gansbacher B; Brew BJ
Ann Intern Med; 1990 Jun; 112(11):812-21. PubMed ID: 1971504
[TBL] [Abstract][Full Text] [Related]
16. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma.
Straus DJ; Duvic M; Kuzel T; Horwitz S; Demierre MF; Myskowski P; Steckel S
Cancer; 2007 May; 109(9):1799-803. PubMed ID: 17366595
[TBL] [Abstract][Full Text] [Related]
17. Severe hypotension following inadvertent intravenous administration of interferon alfa-2a.
Hanson DS; Leggette CT
Ann Pharmacother; 1997 Mar; 31(3):371-2. PubMed ID: 9066950
[No Abstract] [Full Text] [Related]
18. Cutaneous local necrosis following interferon injections.
Cnudde F; Gharakhanian S; Luboinski J; Dry J; Rozenbaum W
Int J Dermatol; 1991 Feb; 30(2):147. PubMed ID: 2001907
[No Abstract] [Full Text] [Related]
19. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma.
Olsen EA; Rosen ST; Vollmer RT; Variakojis D; Roenigk HH; Diab N; Zeffren J
J Am Acad Dermatol; 1989 Mar; 20(3):395-407. PubMed ID: 2783939
[TBL] [Abstract][Full Text] [Related]
20. Non-pegylated and Pegylated Interferon Alpha-2a in Cutaneous T-cell Lymphoma and the Risk of Severe Ocular Side-effects.
Albrecht JD; Ninosu N; Barry D; Albrecht T; Schaarschmidt ML; Goerdt S; Nicolay JP
Acta Derm Venereol; 2022 May; 102():adv00722. PubMed ID: 35506362
[No Abstract] [Full Text] [Related]
[Next] [New Search]
